Skip to main content
iwCLL 2025 Main banner
Final Program


iwCLL X / Twitter

Poster

1424 - Safety Analysis of Fixed-Duration Acalabrutinib-Venetoclax Combinations vs Chemoimmunotherapy: A Post Hoc Analysis From the Phase 3 AMPLIFY Trial

    Primary Author / Presenter(s)

  • JS

    John Seymour, MBBS, PhD, FRACP

    Director, Department of Haematology
    Peter MacCallum Cancer Centre & Royal Melbourne Hospital
    Melbourne, Victoria, Australia

    • Co-Author(s)

  • AA

    Andrew Aw, MD

    Doctor
    Ottawa Hospital, Ontario, Canada

  • VR

    Vincent Ribrag, MD, PhD

    Institut Gustave Roussy
    Villejuif, Ile-de-France, France

  • GC

    Guillaume Cartron, MD, PhD

    Head of Hematology Department
    Centre Hospitalier Universitaire de Montpellier
    Montpellier, France

  • Arnon P. Kater, MD, PhD

    Vice Chair, Hematologist & Principal Scientist
    Department of Hematology, Amsterdam UMC, Cancer Center Amsterdam, University of Amsterdam, and HOVON
    Amsterdam, Noord-Holland, Netherlands

  • KE

    Ki-Seong Eom, MD

    Catholic Hematology Hospital, Seoul St. Mary’s Hospital, College of Medicine, the Catholic University of Korea
    Seoul, Seoul-t'ukpyolsi, Republic of Korea

  • AS

    Alan Skarbnik, MD

    Lymphoma and CLL Program, Novant Health Cancer Institute
    Charlotte, North Carolina, United States

  • AT

    Alessandra Tedeschi, MD

    ASST Grande Ospedale Metropolitano Niguarda
    Milan, Italy

  • MW

    Malgorzata Wach, MD

    Medical University of Lublin
    Lublin, Lubelskie, Poland

  • JH

    Jing-Zhou Hou, MD, PhD

    University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania, United States

  • AI

    Arpad Illes, MD

    University of Debrecen
    Debrecen, Hajdu-Bihar, Hungary

  • BS

    Batul Suterwala, MD

    AstraZeneca
    South San Francisco, California, United States

  • AC

    Anthony J. Corry, PharmD

    AstraZeneca
    Gaithersburg, Maryland, United States

  • EJ

    Ellie John, PhD

    AstraZeneca
    Cambridge, England, United Kingdom

  • TF

    Toshifumi Fujimori, PhD

    AstraZeneca
    Cambridge, England, United Kingdom

  • Jennifer R. Brown, MD, PhD

    Director, CLL Center, and Institute Physician; Worthington Margaret Collette Professor of Medicine in the Field of Hematologic Oncology
    Dana-Farber Cancer Institute, Harvard Medical School
    Boston, Massachusetts, United States